A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Last updated on July 2021Recruitment
- Recruitment Status
- Withdrawn
- Estimated Enrollment
- 40
Summary
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Metastatic Pancreatic Cancer
- Pancreatic Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01510561
- Collaborators
- Not Provided
- Investigators
- Study Chair: William A Wegener, MD, PhD Gilead Sciences
Get Well Soon